
Sign up to save your podcasts
Or


Welcome to Heart Doc VIP! This week, Dr. Kahn tackles a series of mini-topics including the use of colchicine in treating heart disease, the crucial role of oral health in managing atrial fibrillation, and why beta-blockers may not benefit many heart attack patients.
Plus, hear Dr. Kahn's thoughts on Valter Longo, Ph.D.'s insights about the "5Ps" that are excessively present in our diets. Also, check out the newly available L-Protein, a plant-based protein, at prolonfmd.com/Drkahn.
Our main discussion centers on the recent findings from the TACT2 trial, where intravenous chelation therapy in 1,000 heart patients followed over four years failed to improve outcomes. This result is particularly disheartening following the promising TACT trial published in 2013, and it likely signals the end of funded research for chelation therapy.
By Dr. Joel Kahn4.6
469469 ratings
Welcome to Heart Doc VIP! This week, Dr. Kahn tackles a series of mini-topics including the use of colchicine in treating heart disease, the crucial role of oral health in managing atrial fibrillation, and why beta-blockers may not benefit many heart attack patients.
Plus, hear Dr. Kahn's thoughts on Valter Longo, Ph.D.'s insights about the "5Ps" that are excessively present in our diets. Also, check out the newly available L-Protein, a plant-based protein, at prolonfmd.com/Drkahn.
Our main discussion centers on the recent findings from the TACT2 trial, where intravenous chelation therapy in 1,000 heart patients followed over four years failed to improve outcomes. This result is particularly disheartening following the promising TACT trial published in 2013, and it likely signals the end of funded research for chelation therapy.

779 Listeners

1,542 Listeners

3,471 Listeners

875 Listeners

716 Listeners

3,415 Listeners

2,638 Listeners

3,470 Listeners

9,194 Listeners

150 Listeners

2,322 Listeners

847 Listeners

300 Listeners

1,246 Listeners

320 Listeners